If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Developing new drugs is no easy feat. As much as 95 percent of new compounds fail along the path to becoming clinically available. Attrition is especially high for drugs treating the central nervous system. The ones that do succeed rack up an average cost of $1.8 billion. So researchers are increasingly turning to the bottles already on the shelf. Proved safe for human consumption and often understood at a molecular level, today's familiar pills might just be tomorrow's medical discovery. Sometimes one man's side effect is another man's cure.
If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.
I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.
If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.
